Company Overview

Microbot Medical Inc. is a medical technology company focused on the development of robotic-assisted endovascular technologies intended to improve minimally invasive surgical procedures. The company operates within the broader medical device and surgical robotics industries, with a primary emphasis on robotically controlled catheter-based interventions used in vascular and interventional procedures. Its core development platform is the LIBERTY Endovascular Robotic System, which is designed to enable remote manipulation of endovascular devices while reducing radiation exposure and physical strain for physicians.

The company’s primary strategic focus is advancing robotic technologies that support precision navigation in neurovascular, cardiovascular, and peripheral vascular interventions. Microbot Medical has positioned itself as a smaller specialized entrant within the surgical robotics market by concentrating on compact, disposable, and remotely operated robotic systems rather than large-scale operating room robotics platforms. The company traces its origins to Israeli medical robotics research and became publicly traded in the United States through a corporate restructuring and merger process involving prior medical technology assets. Public disclosures and regulatory filings consistently identify robotic endovascular intervention as the company’s principal business activity.

Business Operations

Microbot Medical primarily operates through the development and commercialization efforts surrounding the LIBERTY Endovascular Robotic System and related robotic catheter technologies. The company has historically generated limited revenue, with operations primarily funded through equity financing and capital raises as it advances regulatory approvals, clinical studies, and product development activities. Its business model centers on obtaining regulatory clearances, expanding intellectual property protections, and eventually commercializing robotic systems and disposable components for hospitals and interventional centers.

The company’s operations include research and development activities in both the United States and Israel. Microbot Medical controls intellectual property related to robotic navigation, catheter manipulation, and remote interventional procedures through patents and proprietary technologies. Public filings also reference collaborations with medical institutions and strategic technology relationships supporting product validation and development. The company’s operational structure remains relatively streamlined compared with larger medtech firms, with substantial resources allocated toward engineering, regulatory affairs, and clinical advancement activities.

Strategic Position & Investments

Microbot Medical’s strategic direction is centered on advancing robotic-assisted endovascular intervention platforms capable of improving procedural efficiency, physician ergonomics, and precision in minimally invasive care. A major component of its growth strategy involves pursuing U.S. Food and Drug Administration regulatory milestones for the LIBERTY Endovascular Robotic System, alongside broader commercialization planning in interventional medicine markets. The company has emphasized the potential for remote operation capabilities and disposable architecture to differentiate its system from more complex and capital-intensive robotic platforms currently in the market.

The company has invested significantly in research and development and intellectual property expansion. Public disclosures reference development efforts tied to autonomous navigation support, remote procedural operation, and enhanced robotic catheter control technologies. Microbot Medical has also highlighted opportunities in neurovascular and cardiovascular intervention segments as long-term growth areas. While the company remains comparatively small in scale, its strategic positioning is aimed at participating in the growing robotic surgery and minimally invasive intervention sectors, which continue to attract investment and clinical adoption across global healthcare systems.

Geographic Footprint

Microbot Medical maintains operational and corporate activities across both the United States and Israel. The company’s corporate headquarters are located in the United States, while portions of its research and development activities have historically been conducted through Israeli operations and engineering teams. Its regulatory and commercialization focus has been heavily oriented toward the U.S. healthcare market due to the significance of FDA clearance pathways and the size of the American interventional procedures market.

Although the company does not currently maintain the global commercial footprint of larger medical device manufacturers, it has identified broader international opportunities within robotic-assisted endovascular intervention markets. Public company materials indicate strategic interest in future expansion into additional healthcare systems and international procedural markets as regulatory approvals and commercialization activities progress.

Leadership & Governance

Microbot Medical’s leadership team is composed of executives with backgrounds in medical devices, healthcare technology commercialization, robotics, and finance. The company’s governance structure follows standard U.S. public company practices, including oversight by a board of directors and executive leadership responsible for regulatory strategy, product development, capital allocation, and commercialization planning. Management communications and investor materials consistently emphasize innovation in minimally invasive robotic intervention technologies and long-term value creation through regulatory and clinical advancement.

Key executives identified in public filings and company disclosures include:

• Harel Gadot – Chairman, President and Chief Executive Officer
• Yossef Dagan – Chief Financial Officer
• Ronen Menashe – Chief Technology Officer
• Yehuda Weizman – Vice President of Research and Development

The company’s leadership strategy has focused on advancing the regulatory pathway for the LIBERTY Endovascular Robotic System, expanding strategic partnerships within the healthcare sector, and positioning the company within the evolving robotic-assisted surgery market. Public disclosures, including SEC filings, investor presentations, and corporate communications, consistently support these leadership and strategic priorities.